Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALLMARK
NCT05938712Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin, semaglutide in kidney transplantation, sponsored by University Health Network. Started Oct 2023; status: recruiting.
02
Drugs
dapagliflozinsemaglutide
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT05938712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938712.